{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"description":"DOR is defined as the time between the date of the first documented response (complete response \\[CR\\] or partial response \\[PR\\]) and the date of progression.","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"populationDescription":"As there were no participant achieving response (CR or PR) during escalation phase of the study (only stable disease was achieved). Therefore the evaluation of duration of response could not be performed.","reportingStatus":"POSTED","timeFrame":"Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)","title":"Duration of Response (DOR)","type":"SECONDARY"}